Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
On Yahoo the RSPI 1 yr target is .30, and someone just bought for $1.15. Anyone of you buyers?
Well said.
Hopefully people are listening.
My losses on this POS still sting!
Major HoldersCurrency in USD
Breakdown
25.84% % of Shares Held by All Insider
0.00% % of Shares Held by Institutions
0.00% % of Float Held by Institutions
0 Number of Institutions Holding Shares
Direct Holders (Forms 3 and 4)
Name Shares Date Reported
MANUSO JAMES S J 74,252 Sep 12, 2017
This says it all.
No need to wonder....
We're all still screwed!
Words of wisdom..
NEVER FALL IN LOVE WITH A STOCK!!!!
IF A STOCK ISN'T GOOD ENOUGH TO ATTRACT INSTITUTIONAL INVESTORS STAY AWAY!!!!!!!!!
No deal no selling. Simple.
Deal will more then likely bring dilution.
But no deal yet. I wouldn't buy anymore shares unless they got a great deal. Past management got peanut shells.
Like watching a pond dry up. Slow and painful, hoping for rain.
Funny don't hold your breath. Sleep apnea is a target indication. Ironic
Yes, they are playing ship captain crew in the back room of the local deli, using our money to gamble with. I have unfortunately lost tons betting on Ampakines, and lost big. Don't hold your breath.
The general has been missing in action for a long time. I wonder if he has any opinion to share with us.
I would love to hear from him!
I have been watching what's left of my substantial investment in this trash circle the drain for quite some time now.
It feels like the end is near to me.
Any thoughts?
This is sad.
Food4thought
From what I gather he is still looking for financing.
However, it looks like we the shareholders are on the hook once again.
Regards,
Dear Jeffrey,
I have been a shareholder since the Cortex days.
I saw my $100,000 dollar investment get wiped out, an only have myself
to blame.
I always felt the potential of the technology exceeded the risk, so I
held on stupidly.
Is there any hope for us? We need some kind of communication. So
validation from you.
Sincerely,
His reply is as follows;
From: Jeff Margolis <jmargolis@respirerx.com>
Date: 5/17/17 12:00 PM (GMT-06:00)
To: Bill Paprocki <Bill@servosolutionsinc.com>
Subject: Re: concerned shareholder
Bill:
I’m not sure my answer will be adequate for you, but I do believe there is promise for this company. However, even if that promise is achieved, I cannot assure you that you will achieve a positive return on your earlier investment or even a partial return of what is currently unrealized losses.
A statement of that belief in the promise of the company is our general willingness to have deferred our cash compensation and receive equity or equity-linked (options) as compensation. I, and our Chairman (who is also our Chief Scientific Officer) have been involved with the Company since March 22, 2013. Our Chairman invested $250,000 in our first financing since then (March/April 2014) and has invested again. Since March 2013, although, we have accrued our compensation in accordance with employment contracts that went into effect on August 18, 2015 (and earlier than that without contracts), we have not received a single dollar of that cash compensation to date. The entire accrual remains on the Company’s books. The same is true for our Vice Chairman and CEO, who joined us on August 18, 2015. He invested $250,000 at that time and has since invested more. We have made progress in financing the company although we can always use more finance. Two important clinical studies have been completed.
In short, I do believe in the economic and human health value of what we are doing and would expect it to be recognized in the stock price. That being said, we can never guarantee that.
We can say that we always do what we believe is in the best interests of our shareholders which includes the management team and the Board of Directors.
Sincerely,
Jeff
Jeff Eliot Margolis
Vice President, Secretary, Treasurer, Interim CFO & Member of the Board of Directors
RespireRx Pharmaceuticals Inc.
354 Widow Gavits Road
PO Box 1167
Volume isn't over the top. Nobody knows at this point when, what, or why. I think this goes to 20 plus soon.
The other trials are easy compared to the Sustol trials.
Faster. Don't be surprised if the hernia, or bunion study results come before the shorts have their way again.
Keep 1 thing in mind. Any approval is a giant step for this company.
It's the validation of the delivery system that is most meaningful.
I think they get all of the indications, plus I think it happens tomorrow or Thursday. It will be one month. Don't be surprised to see a series of press releases. $25+ by the 20th, IMHO..
Bot's trading using algorithmic trading system.
buy/sell all day.
I always felt Sustol was simply the validation of the delivery system. Any approval means they can move forward with dozens of indications. Pain management is big!
This whole thing is about nano technology applied to existing approved meds. Very interesting and an easy path to take. Tang is brilliant.
Typically, response takes 3 to 4 weeks.
Labeling is serious stuff. Think about it.
Don't speculate because it will drive you crazy.
Even if they don't receive across the board approval we will see the news for hernia trials right away,because the trials run quickly. I'm looking for a slam!
This has been trading by compu-bots for a while.
Today showed me the reversal of pattern. Almost identical.
Their will be more up days to come, and I think there will be an announcement soon. Landec Corps medical division Lifecore, is doing the manufacturing for them, and I don't anticipate any problems there. They are solid. Hang tight. We'll hear real soon, I hope!
We are going nowhere fast.
Same old corx, just a new name to curse!
No. I won't go overboard like I did with CORX.(-120k) Trading for me is a hobby. I own a servo motor repair shop. Automation, that's where the big bucks are. I grow 20% a year, and don't see is slowing down. But if HRTX gets the pass this time around (3rd try) I'll be smiling.
gfp927z,
Thanks, I am long on this one, and hope to finally have a winner.
The management seems to have crossed their T's and dotted their I's this time. But like you said, things happen. If it does get approved this one will keep flying. The validation of the delivery system opens the door to limitless indications. Pain management seems to be a no brainer. Check out the pipeline. Hope RSPI can do the same in the near future. It's alive!!!
We have another month till the FDA rules on this one.
The insiders have all been buying. No sales as far as I can see.
How will the hedgies play the final month. Will there be a big short squeeze? Will the third time be the charm?
I am hoping to see a run up to $35. Then $50 to $55 on approval.
If it flies...........?
gfp927z,
You're right about everything. AP Pharma, now known as Heron Pharma did just that. The stock actually was trading below Corx. I believe .17 cents. It's going for round three with the FDA and a decision for approval is coming by end of Feb. They are trading at $21.50, and have run up as high as $42.
There is always hope!
There is no bottom.
thanks,
I think you nailed it.
I have been a shareholder for a very long time, and without some kind of miracle will never see my investment. Like many of you I am wondering if this company is going to survive, or if they will go belly up. Anyone have any insight into this.
Yes, someone dumped 1.5 million shares today.
I think the mice from the test found a chunk of cheese on a spring trap. We're going nowhere.
This is news!
Cortex Pharmaceuticals, Inc. Announces Publication of Research Results on the Use of Ampakines CX1739 and CX717 in the Treatment of Respiratory Disorders
Company Focusing on Strategic Research Initiatives Involving Respiratory Disorders
Cortex Pharmaceuticals, Inc.
May 4, 2015 9:00 AM
GlobeNewswire
????
GLEN ROCK, N.J., May 4, 2015 (GLOBE NEWSWIRE) -- Cortex Pharmaceuticals, Inc. (CORX) ("Cortex" or the "Company") announces the recent publication of two key scientific papers co-authored by the Chairman of the Company's Scientific Advisory Board, Dr. John Greer, Ph.D. that show the positive effects of the Company's ampakines CX1739 and CX717 in treating respiratory distress in a perinatal premature rat pup model and a genetic mouse model of Pompe Disease. Cortex is a leader in developing drugs for respiratory disorders, particularly sleep apnea (both obstructive and central) and drug-induced respiratory depression.
Premature infants exhibit frequent apneic events and have weak endogenous respiratory drive, which are some of the most persistent and troubling problems in neonatal intensive care. Apnea of prematurity occurs in varying degrees in more than 85% of infants who are born at less than 34 weeks of gestation. In a paper entitled "Ampakines Enhance Weak Endogenous Respiratory Drive and Alleviate Apnea in Perinatal Rats" in the American Journal of Respiratory and Critical Care Medicine, Volume 191, Number 6, March 15, 2015 (http://www.atsjournals.org/doi/abs/10.1164/rccm.201410-1898OC - .VUZzCEskhuZ), Ren, Ding and Greer describe experiments in perinatal rats that demonstrate increased inspiratory drive in response to Cortex's ampakine CX1739. The authors report that CX1739 reduces apneas and improves ventilation in perinatal rats, providing pharmacologic evidence that CX1739 should be considered for development to treat this indication, which is currently a poorly met clinical need.
In an editorial review in the same journal, Dr. Christopher G. Wilson, Ph.D., Department of Pediatrics and Center for Perinatal Biology, Loma Linda University, writes of the results, "according to these data, the ampakine CX1739 is a promising candidate for replacing or enhancing caffeine therapy in neonates. Further preclinical and clinical trials focused on the use of CX1739 in the neonatal intensive care unit are the next logical benchmark."
In another publication entitled "Ampakines Stimulate Respiratory Motor Output and Ventilation in a Murine Model of Pompe Disease," in the American Journal of Respiratory Cell and Molecular Biology, January 8, 2015 (http://www.ncbi.nlm.nih.gov/pubmed/?term=greer+pompe+CX717), ElMallah, Greer, Fuller, et al, describe experiments in which CX717, another of the Company's ampakines, stimulates respiratory neuromotor output and ventilation in a genetic mouse model of Pompe Disease, suggesting that ampakines may have potential as an adjunctive therapy in Pompe Disease.
Dr. John Greer, Ph.D., Head of the Neuroscience and Mental Health Institute at the University of Alberta, and a co-author on both publications, has dedicated his research to understanding the basic mechanisms of breathing and discovering the use of ampakines to promote respiration. Dr. Greer is the inventor of the use patents licensed by Cortex for the use of ampakines that the Company is developing for the treatment of drug-induced respiratory depression and central and mixed-sleep apnea. "The low-impact ampakines that we are studying, CX717, CX1739 and CX1942, have the potential to treat a wide variety of respiratory disorders that have few, if any, treatment options," said Dr. Greer. "We are pleased to see that our work is leading to the development of clinically meaningful compounds that have the potential to help patients breath."
"These publications by our research partners at the University of Alberta and the University of Florida demonstrate the Company's commitment to basic research in respiratory disorders," said Richard Purcell, Senior Vice President of Research and Development for Cortex. "We are nearly ready to initiate our Phase 2 clinical program with the ampakine CX1739 in the prevention of respiratory depression caused by opiates and propofol, and we are excited about the opportunity to expand our development efforts in respiratory care, guided by these scientific discoveries."
Related Quotes
CORX0.040.00%
Cortex Pharmaceuticals, Inc.
Watchlist
0.040.00(0.00%)
OTC Markets11:36 AM EDT
CORTEX PHARMACEUTICALS INC/DE/ Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online 1 day 3 hrs ago
CORTEX PHARMACEUTICALS INC/DE/ Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and E EDGAR Online 4 days ago
More
About Cortex Pharmaceuticals, Inc.
Cortex Pharmaceuticals, Inc. is a biopharmaceutical company currently engaged in the discovery and development of drugs for the treatment of respiratory disorders. Drug candidates are currently derived from two platforms, as described below.
The first platform is a class of compounds known as ampakines that act as positive allosteric modulators of AMPA glutamate receptors. Several ampakines in both oral and injectable form are being developed by Cortex for the treatment of drug induced respiratory depression caused by opiates and anesthetics. In preclinical and clinical studies, such drugs have shown preliminary efficacy in central sleep apnea and restored normal respiration without altering the analgesic effects of opiates or the anesthetic effects of drugs such as propofol. The Company's compounds belong to a new generation of ampakines that do not display the undesirable side effects displayed by previous compounds.
The second platform is the class of compounds known as cannabinoids, in particular, dronabinol. In a double-blind, placebo-controlled, dose-ascending Phase 2A clinical study conducted by the Company, dronabinol significantly improved measures of sleep apnea in a group of patients with obstructive sleep apnea. A larger 120 patient, double-blind, placebo-controlled Phase 2B clinical study is currently being conducted by the University of Illinois and is being funded by the National Institutes of Health.
Additional information about Cortex and the matters discussed herein can be obtained on the Company's website at www.cortexpharm.com or in the Company's filings on EDGAR at www.sec.gov
8K.
Something?
Anyone notice this?
Yes by who?
Not Corx.
Thank you, for the detailed response.
I can't see it being as valuable as Ampakines for sleep apnea, however combining the two....
Delta 9?
Can anyone fill in the blanks...
We have a long way to go before it explodes.
But it's nice to see some action for a change.
Maybe some hunt left in the old dog.
I am happy with the direction. It seems like the path of least resistance. Good luck to all bag holders. Our day will come!
I guess I'll have to go back to lining my birds cage with newspaper.
The stock certs are becoming more valuable.
The web site has more to say about the direction of the company too.
But, can they pull it off, raise money, and take us back to 2005?
So funny but true. Sad, and I am still holding this crap.
Worst mistake of my life! Other then my ex wife.